Bertis Renews Mass Spectrometry-based Omics Analysis Service 'PASS'

- Incorporating insights from two years of customer needs and staying abreast of the latest research and technological advancements.

- Enhancing tailored services for clients in areas such as R&D, biotechnology, and pharmaceuticals.

On April 4th, Bertis, a company specializing in the development of proteomics-based precision medicine technology (led by CEOs Dong-young Noh and Seung-man Han), announced the renewal of their PASS (Pan-omics Analysis Service & Solution), which provides mass spectrometry-based omics analysis service. This renewal reflects both customer needs and the latest research and technological trends.

Pan-omics is the integration of complex “omics” datasets generated from the subfields of genomics, transcriptomics, proteomics, and metabolomics to increase the understanding of pathophysiology, diagnosis, and treatment of diseases. PASS, under the slogan 'Through PASS to PATH', is an insightful analysis solution leveraging Bertis’ pan-omics knowledge and know-how coupled with its proprietary bioinformatics and AI technology to deliver analytical services including protein biomarker discovery, validation, drug research and development, production, and more.

Bertis announced the renewal of their PASS, which provides mass spectrometry-based omics analysis service.

This renewal reflects both customer needs and the latest research and technological trends.

The recent overhaul of the PASS service was driven by a commitment to align with customer needs and the latest research, and technological advancements observed over the two-year period since its launch in May 2022. Whereas the previous iteration comprised four services centered around foundational protein research and its secured technologies, the revamped PASS offers a more structured service portfolio, ranging from analytical services essential for research to analysis package solutions required for research and development in the biopharmaceutical sector. As a result, the augmentation of tailored services, specifically catered to the objectives of each client, such as biotech firms pioneering novel modalities like exosomes and PROTAC, as well as CDMO enterprises, has been notably reinforced.

The renewed PASS service is structured around five core components, each designed to meet specific analytical needs. INTEGRATED PROTEOMICS provides qualitative and quantitative analysis of whole proteomes. TARGETED PROTEOMICS facilitates quantitative analysis of target proteins using the MRM/PRM methods, while SINGLE CELL PROTEOMICS offers qualitative and quantitative analysis of proteins in single cells. LIPIDOMICS provides qualitative and quantitative analysis of lipids using 20 standards, BIOINFORMATICS enables the bioinformatics-based proteomic data analysis and interpretation. For more information on the service process and updated FAQs about PASS, please visit the service introduction page on the Bertis website at https://bertis.com/ko/solution/pass.php

Seong-jun Park, Director of the PASS Center, emphasized, "In the past year, PASS has strategically pursued a diverse range of projects and diligently uncovered market demand, resulting in a revenue growth of over two-fold compared to the preceding year. With a commitment to delivering superior, tailored solutions to our clients, we have undertaken a comprehensive renewal initiative." He continued, "We aspire for PASS services to serve as a catalyst for expediting the development of new pharmaceuticals and products, empowering enterprises to efficiently access a wealth of diverse and precise protein data."